Decoding the effects of the gut microbiome on neoadjuvant chemotherapy. Recent findings indicate that the intestinal microbiota play a critical role in human physiological and pathophysiological processes. Evidence is increasing that the composition of the microbiota regulates the efficacy of anticancer therapy and that targeting the microbiota may improve drug efficacy and/or reduce adverse effects.
Our aim is to comprehensively study the association between gut microbiota composition and the degree of clinical and pathological tumor response to chemotherapy, as well as the profile of drug toxicity in patients receiving neoadjuvant treatment for locally advanced pancreatic and rectal cancer, as well as for patients with colorectal liver metastases. Such findings highlight the potential therapeutic utility of manipulating the human gut microbiota in order to improve cancer treatment and develop the next-generation cancer therapies.
Nir Lubezky MD
Tel-Aviv Sourasky Medical Center